If your insurer will not cover a GLP-1 and the denial is a true benefit exclusion, an appeal is usually a long shot. Paying cash is often the faster route, and the gap between list price and real self-pay price is enormous once you know where to look. Here is the honest landscape, from most to least established.
When cash-pay beats appealing
Start with the type of denial. If the plan simply excludes weight-loss medication as a benefit, appealing rarely changes that, and the months spent fighting are months without treatment. If instead the denial is a prior-authorization or medical-necessity issue, it is usually worth appealing first, because a covered copay can be lower than any cash price. Cash-pay is the answer to a hard exclusion, not a substitute for a winnable appeal.
The cash market has grown quickly. GLP-1 medications rose from about 6.9% of pharmacy claims in 2023 to 10.5% in 2025, and a large share of that spending now happens outside traditional insurance.
Brand self-pay: NovoCare and LillyDirect
The pharmacy list prices are the worst-case number, not what most people pay. Wegovy lists around $1,349 per package and Zepbound around $1,059 per month. Direct from the manufacturer, the picture is very different. Novo Nordisk's NovoCare sells Wegovy to self-pay patients in a roughly $149 to $399 per month range depending on the option, and Eli Lilly's LillyDirect sells Zepbound in a roughly $299 to $449 per month range as of mid-2026. These are the branded, FDA-approved medications, which is their main advantage.
Compounded telehealth options compared
Licensed telehealth providers offer compounded semaglutide and tirzepatide, and these are frequently the lowest monthly cost, often in the low hundreds of dollars. The tradeoff is that compounded medications are not FDA-approved and their long-term availability is uncertain. The neutral landscape here is broad: national names like Ro, Hims, Found, and Noom all operate in this space, alongside more specialized compounding-focused providers. Prices, medication types, and included support vary widely, so compare the all-in monthly cost rather than the headline number.
If you want a like-for-like view, our telehealth price comparison lines up providers side by side, and the GLP-1 cost guide covers savings cards and assistance programs.
What to watch for
Two things matter most. First, FDA status: because the semaglutide and tirzepatide shortages were declared resolved, compounding is now subject to enforcement limits, so confirm a provider can actually continue supplying your medication before you commit. Second, the all-in cost: some low advertised prices exclude shipping, the visit fee, or later-month pricing, so read the full terms.
How to decide
If you have a covered indication like type 2 diabetes, ask your prescriber whether a covered option fits before paying cash. If not, weigh branded self-pay against compounded telehealth on total monthly cost, medication type, and how much continuity you need. For most people facing a hard exclusion, a compounded telehealth plan is the lowest cost today, with brand self-pay as the FDA-approved alternative.
Sources: Novo Nordisk NovoCare and Eli Lilly LillyDirect self-pay pricing (mid-2026); IFEBP 2025 pulse survey on GLP-1 pharmacy-claim share; FDA shortage-resolution notices for semaglutide and tirzepatide. Self-pay prices change frequently, so confirm current pricing directly with each provider.